Peter E. Merian

UBS AG (Investment Management) (UBS-IM) is the Swiss investment management division of UBS AG, itself a subsidiary of UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. Formerly known as UBS Global Asset Management Switzerland, the firm was founded in 1998 when Union Bank of Switzerland and Swiss Bank Corporation merged. Headquartered in Zurich and has additional office in Basel, UBS-IM manages a range of investment funds and offers investment management services for institutional, corporate and private clients.

ARTICO Partners AG is an independent asset management firm headquartered in Zurich, Switzerland. The firm was founded in 2004 and offers Luxemburg-based institutional funds exclusively to professional and qualified investors.

Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA.

Esocap AG is a privately funded company based in Basel, Switzerland. The Swiss company's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform. The company is cooperating with key R&D and industrial partners, including the University of Greifswald, where the Esocap technology was invented by Prof. Werner Weitschies and his team. Esocap has filed several worldwide patents for their technology, which includes a capsule holder and production methods. The CEO of the company is Isabelle Racamier.